Postoperative Use of the Chemopreventive Vitamin K2 Analog in Patients with Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zhong, Jian Hong ^a   Mo, Xin Shao ^a   Xiang, Bang De ^a   Yuan, Wei Ping ^a   Jiang, Jin Fang ^a   Xie, Gui Sheng ^a   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MENATETRENONE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE RISK; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; HUMANS; LIVER NEOPLASMS; POSTOPERATIVE CARE; PUBLICATION BIAS; RECURRENCE; RISK; TREATMENT OUTCOME; VITAMIN K 2;

EID: 84874746017     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058082     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, et al. (2007) Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 205: 27-36.
3. Singal AK, Freeman DH, Anand BS, (2010) Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32: 851-858.
4. Zhong JH, Li LQ, (2010) Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 40: 943-953.
5. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, et al. (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807.
6. Prabhoo R, Prabhoo TR, (2010) Vitamin K2. a novel therapy for osteoporosis. J Indian Med Assoc 108: 253-254.
7. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, et al. (2004) Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292: 358-361.
8. Chu KJ, Lai EC, Yao XP, Zhang HW, Lau WY, et al. (2010) Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation-a systematic review and meta-analysis. Asian J Surg 33: 120-126.
9. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, et al. (2009) Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 51: 315-321.
10. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, et al. (2006) The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106: 867-872.
11. Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, et al. (2007) Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 22: 518-522.
12. Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, et al. (2007) Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 54: 2073-2077.
13. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, et al. (2011) Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 54: 532-540.
14. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896-1900.
15. Kubota K, Sawada T, Kita J, Shimoda M, M K, (2011) Effect of menatetrenone, a vitamin K2 analog, on recurrence of hepatocellular carcinoma after surgical resection- Final results of randomized controlled study. Eur J Cancer 47 SUPPL. 1: S470.
16. Hosho K, Okano J, Koda M, Murawaki Y, (2008) Vitamin K2 Has No Preventive Effect on Recurrence of Hepatocellular Carcinoma after Effective Treatment. Yonago Acta medica 51: 95-99.
17. Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, et al. (2012) Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res 32: 5415-5420.
18. Sakaguchi T, Suzuki S, Morita Y, Oishi K, Suzuki A, et al. (2010) Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today 40: 638-645.
19. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, et al. (2008) PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 75 Suppl 1: 91-98.
20. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, et al. (2009) Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 43: 482-488.
21. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM, (2010) Prognostic and diagnostic value of des-gamma-carboxy prothrombin in liver cancer. Drug News Perspect 23: 498-508.
22. Nakamura M, Nagano H, Noda T, Wada H, Ota H, et al. (2006) Vitamin K2 has growth inhibition effect against hepatocellular carcinoma cell lines but does not enhance anti-tumor effect of combination treatment of interferon-alpha and fluorouracil in vitro. Hepatol Res 35: 289-295.
23. Li L, Qi Z, Qian J, Bi F, Lv J, et al. (2010) Induction of apoptosis in hepatocellular carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53 and independent of the intrinsic apoptotic pathway. Mol Cell Biochem 342: 125-131.
24. Azuma K, Urano T, Ouchi Y, Inoue S, (2009) Vitamin K2 suppresses proliferation and motility of hepatocellular carcinoma cells by activating steroid and xenobiotic receptor. Endocr J 56: 843-849.
25. Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, et al. (2007) Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res 13: 2236-2245.
26. Yamamoto T, Nakamura H, Liu W, Cao K, Yoshikawa S, et al. (2009) Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). J Gastroenterol 44: 228-235.
27. Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, et al. (2010) Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 138: 1931-1942.